我們已在上線!
進一步了解
RCOR
Renovacor, Inc.
RCOR
RCOR
已下市
RCOR已於2022年11月30日下市。
關於: Renovacor Inc is a preclinical stage gene therapy company developing a pipeline of innovative and proprietary AAV-based gene therapies for BAG3 gene mutation-associated diseases in areas of high unmet medical need. Its therapeutic focus is on cardiovascular disease, with a lead program in BAG3 mutation-associated dilated cardiomyopathy.
員工: 19
新聞
正面
中性
負面
市場情緒
3個月
正面
0%
中性
0%
負面
0%
我們尚未收到任何關於RCOR的最新新聞文章。
價格圖表採用Lightweight Charts™實作